Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
140.31%
-
Total 13F principal
-
$503,553,600
-
Principal change
-
-$8,354,000
-
Total reported market value
-
$706,927,628
-
Number of holders
-
45
-
Value change
-
-$1,700,309
-
Number of buys
-
15
-
Number of sells
-
20
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q3 2025
As of 30 Sep 2025,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
45 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$503,553,600
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, Linden Advisors LP, Weiss Asset Management LP, TENOR CAPITAL MANAGEMENT Co., L.P., CITADEL ADVISORS LLC, Graham Capital Management, L.P., Balyasny Asset Management L.P., Voya Investment Management LLC, CAPSTONE INVESTMENT ADVISORS, LLC, and 683 Capital Management, LLC.
This page lists
45
institutional bondholders reporting positions
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.